advanc
stage
cancer
difficult
control
use
convent
therapi
chemotherapi
surgeri
radiat
therefor
new
innov
therapi
urgent
requir
order
combat
high
mortal
morbid
associ
cancer
antigenspecif
immunotherapi
emerg
attract
approach
treatment
cancer
sinc
abil
specif
erad
system
tumor
control
metastas
without
damag
normal
cell
exampl
recent
studi
immunotherapi
use
synthet
long
peptid
vaccin
deriv
human
papillomaviru
type
antigen
led
signific
clinic
respons
patient
precancer
lesion
gynecolog
malign
dna
vaccin
becom
potenti
promis
approach
antigenspecif
immunotherapi
due
safeti
stabil
eas
prepar
review
see
previous
develop
sever
innov
strategi
enhanc
dna
vaccin
potenc
directli
target
dna
dendrit
cell
dc
vivo
via
gene
gun
well
modifi
properti
antigenexpress
dc
review
see
one
strategi
enhanc
dna
vaccin
potenc
use
intracellular
target
strategi
enhanc
mhc
class
antigen
present
process
dc
previous
studi
linkag
calreticulin
crt
protein
locat
endoplasm
reticulum
er
review
see
sever
antigen
includ
human
papillomaviru
nucleocapsid
protein
sever
acut
respiratori
syndrom
coronaviru
intraderm
administr
dna
encod
crt
link
target
antigen
led
signific
increas
antigenspecif
cell
immun
respons
impress
antitumor
effect
vaccin
mice
thu
crt
shown
highli
potent
enhanc
antigenspecif
immun
respons
antitumor
effect
gener
dna
vaccin
sever
preclin
model
anoth
import
innov
cancer
therapi
involv
employ
immunomodulatori
agent
imiquimod
review
see
exact
mechan
action
imiquimod
analog
activ
immun
system
still
activ
investig
nevertheless
known
imiquimod
activ
immun
cell
tolllik
receptor
commonli
involv
pathogen
recognit
cell
surfac
cell
activ
imiquimod
via
secret
cytokin
evid
imiquimod
appli
skin
lead
activ
langerhan
cell
subsequ
migrat
local
lymph
node
activ
adapt
immun
system
cell
type
activ
imiquimod
includ
nk
cell
macrophag
blymphocyt
current
studi
hypothes
combin
dna
vaccin
encod
crt
link
topic
applic
imiquimod
site
tumor
lead
increas
infiltr
effectior
immun
cell
site
tumor
result
enhanc
antitumor
effect
tumor
preclin
model
observ
treatment
dna
combin
imiquimod
lead
decreas
number
myeloidderiv
suppressor
cell
mdsc
regulatori
cell
tumor
microenviron
tumorbear
mice
treatment
dna
combin
imiquimod
also
found
lead
enhanc
cell
immun
respons
tumorbear
mice
furthermor
treatment
dna
combin
imiquimod
lead
significantli
improv
antitumor
effect
prolong
surviv
treat
mice
addit
treatment
imiquimod
led
increas
number
cell
cell
tumor
microenviron
furthermor
macrophag
cell
found
play
import
role
antitumor
effect
mediat
treatment
dna
combin
imiquimod
clinic
implic
current
studi
discuss
femal
mice
iab
wk
age
purchas
nation
cancer
institut
mice
maintain
specif
pathogenfre
condit
anim
facil
john
hopkin
hospit
taipei
veteran
gener
hospit
anim
use
complianc
institut
anim
health
care
regul
anim
experiment
procedur
approv
john
hopkin
institut
anim
care
use
committe
taipei
veteran
gener
hospit
experiment
anim
center
product
mainten
cell
describ
previous
cell
grown
rpmi
supplement
vv
fetal
bovin
serum
unitsml
penicillinstreptomycin
mmoll
lglutamin
mmoll
sodium
pyruv
mmoll
nonessenti
amino
acid
mgml
cell
test
shown
free
mycoplasma
contamin
gener
recombin
plasmid
describ
previous
accuraci
dna
construct
confirm
dna
sequenc
gene
gunmedi
intraderm
vaccin
recombin
plasmid
dna
deliv
shave
abdomin
region
mice
use
heliumdriven
gene
gun
biorad
previous
describ
protocol
character
regulatori
cell
mdsc
tumor
microenviron
mice
divid
four
group
untreat
imiquimod
alon
alon
combin
group
mice
inocul
cell
sc
right
leg
untreat
group
mice
regularli
follow
implant
without
specif
treatment
imiquimod
group
mous
receiv
topic
imiquimod
mgmous
site
tumor
everi
two
day
begun
total
treatment
alon
group
mous
vaccin
via
gene
gun
combin
treatment
group
mous
receiv
treatment
schedul
monotherapi
alon
group
tumor
harvest
flow
cytometr
analysi
tumor
cell
either
stain
peconjug
fitcconjug
mab
quantif
regulatori
cell
stain
stain
peconjug
fitcconjug
mab
quantif
mdsc
character
cell
tumor
microenviron
mice
divid
four
group
untreat
imiquimod
alon
alon
combin
group
mice
inocul
cell
sc
right
leg
untreat
group
mice
regularli
follow
implant
without
specif
treatment
imiquimod
group
mous
receiv
topic
imiquimod
mgmous
site
tumor
everi
two
day
begun
total
treatment
alon
group
mous
vaccin
via
gene
gun
combin
treatment
group
mous
receiv
treatment
schedul
monotherapi
alon
group
tumor
harvest
immun
respons
analysi
intracellular
cytokin
stain
pool
tumor
treatment
group
separ
incub
h
ctl
epitop
aa
cell
harvest
stain
use
previous
describ
standard
protocol
sampl
analyz
facscalibur
flow
cytomet
use
cellquest
softwar
analys
shown
carri
gate
lymphocyt
popul
evalu
chang
variou
immun
effector
tumor
microenviron
imiquimod
treatment
mice
divid
two
group
vehicl
treat
imiquimod
treat
implant
mous
receiv
topic
vehicl
cream
imiquimod
mgmous
everi
two
day
initi
total
time
tumor
harvest
hour
last
treatment
tumor
cell
made
singl
cell
suspens
wash
facscan
buffer
stain
surfac
marker
variou
innat
adapt
effector
includ
peconjug
peconjug
fitcconjug
peconjug
peconjug
cell
subject
flow
cytometri
analysi
gate
lymphocyt
popul
order
evalu
monotherapi
alon
combin
treatment
inhibit
tumor
growth
design
twostep
experi
firststep
experi
evalu
antitumor
effect
imiquimod
alon
therapi
mice
divid
group
untreat
imiquimod
treat
implant
subcutan
mice
left
untreat
treat
imiquimod
mgmous
site
tumor
everi
two
day
initi
total
treatment
mice
euthan
tumor
harvest
photograph
tumor
size
comparison
prove
imiquimod
effect
singl
agent
proceed
secondstep
experi
mice
divid
four
group
untreat
imiquimod
alon
alon
combin
group
mice
inocul
cell
sc
right
leg
untreat
group
mice
regularli
follow
tumor
growth
implant
without
specif
treatment
imiquimod
group
mous
receiv
topic
imiquimod
mgmous
site
tumor
everi
two
day
began
total
treatment
alon
group
mous
vaccin
via
gene
gun
combin
treatment
group
mous
receiv
treatment
schedul
monotherapi
alon
group
tumor
size
mice
monitor
measur
everi
day
use
digit
calip
order
identifi
subset
lymphocyt
import
antitumor
effect
combin
treatment
imiquimod
dna
vaccin
mice
divid
group
combin
treatment
without
deplet
combin
treatment
deplet
neutrophil
combin
treatment
deplet
cell
combin
treatment
deplet
macrophag
use
method
similar
describ
previous
mice
implant
treat
imiquimod
mice
either
undeplet
deplet
macrophag
use
clodron
liposom
cell
use
antimous
mab
neutrophil
use
antimous
mab
one
day
day
implant
thereaft
per
week
end
followup
data
express
mean
standard
deviat
sd
repres
least
two
differ
experi
comparison
individu
data
point
tumor
size
made
use
student
ttest
repeat
measur
anova
analysi
varianc
test
differ
surviv
experiment
group
analyz
use
logrank
test
tumor
size
calcul
use
follow
equat
tumor
death
mous
arbitrarili
defin
tumor
diamet
greater
cm
order
determin
number
cell
mainli
compris
regulatori
cell
myeloidderiv
suppressor
cell
tumor
microenviron
tumorbear
mice
treat
dna
imiquimod
inocul
mice
cell
treat
without
topic
imiquimod
mgmous
everi
two
day
start
total
treatment
mice
vaccin
dna
via
gene
gun
untreat
mice
use
control
tumor
harvest
character
presenc
regulatori
cell
myeloidderiv
suppressor
cell
flow
cytometri
analysi
shown
figur
mice
treat
dna
combin
imiquimod
demonstr
significantli
lower
number
myeloidderiv
suppressor
cell
compar
treat
mice
comparison
signific
differ
number
cell
mice
treat
dna
combin
imiquimod
compar
group
thu
data
indic
treatment
imiquimod
combin
dna
vaccin
reduc
number
myeloidderiv
suppressor
cell
tumor
microenviron
treat
mice
order
determin
immun
respons
tumorbear
mice
vaccin
dna
imiquimod
inocul
mice
cell
treat
dna
vaccin
andor
imiquimod
describ
figur
splenocyt
tumorbear
mice
harvest
character
cell
immun
respons
intracellular
cytokin
stain
follow
flow
cytometri
analysi
shown
figur
mice
treat
dna
combin
topic
applic
imiquimod
demonstr
significantli
higher
number
cell
compar
mice
treat
alon
thu
data
indic
treatment
imiquimod
combin
dna
vaccin
significantli
enhanc
cell
immun
respons
treat
mice
order
determin
therapeut
antitumor
effect
gener
tumorbear
mice
vaccin
dna
imiquimod
inocul
mice
cell
treat
dna
vaccin
andor
topic
applic
imiquimod
describ
figur
tumor
growth
monitor
time
shown
figur
mice
treat
dna
combin
imiquimod
demonstr
significantli
lower
tumor
size
time
compar
mice
treat
alon
furthermor
mice
treat
alon
imiquimod
alon
demonstr
significantli
lower
tumor
volum
compar
mice
without
treatment
control
addit
mice
treat
dna
combin
topic
applic
imiquimod
demonstr
significantli
prolong
surviv
compar
mice
treat
alon
figur
thu
data
indic
topic
treatment
imiquimod
combin
therapeut
hpv
dna
vaccin
enhanc
therapeut
antitumor
effect
tumor
treat
mice
order
determin
key
immun
cell
tumor
microenviron
upregul
follow
imiquimod
treatment
mice
implant
divid
two
group
vehicl
treat
imiquimod
treat
mous
receiv
topic
vehicl
cream
imiquimod
everi
two
day
initi
total
time
tumor
harvest
hour
last
imiquimod
treatment
tumor
cell
made
singl
cell
suspens
analyz
presenc
variou
immun
cell
marker
flow
cytometri
analysi
shown
figur
mice
treat
topic
applic
imiquimod
demonstr
significantli
higher
number
cell
includ
nk
cell
well
nkt
cell
inflammatori
cell
tumor
microenviron
compar
mice
treat
vehicl
thu
data
indic
imiquimod
treatment
lead
upregul
cell
inflammatori
cell
tumor
microenviron
order
determin
immun
cell
play
import
role
antitumor
effect
mediat
dna
vaccin
follow
imiquimod
treatment
perform
vivo
deplet
experi
mice
divid
group
mice
implant
subcutan
treat
imiquimod
dna
vaccin
describ
mice
either
deplet
macrophag
use
clodron
liposom
cell
use
antimous
nk
mab
neutrophil
use
antimous
mab
one
day
day
implant
thereaft
per
week
end
followup
undeplet
mice
use
control
shown
figur
treat
mice
deplet
macrophag
cell
demonstr
signific
increas
tumor
growth
compar
undeplet
mice
mice
deplet
neutrophil
thu
data
indic
macrophag
cell
play
import
role
antitumor
effect
mediat
treatment
dna
combin
imiquimod
current
studi
observ
treatment
dna
combin
imiquimod
lead
decreas
number
myeloidderiv
suppressor
cell
cell
tumor
microenviron
tumorbear
mice
treatment
dna
combin
imiquimod
also
found
lead
enhanc
cell
immun
respons
improv
antitumor
effect
prolong
surviv
treat
mice
macrophag
cell
found
play
import
role
antitumor
effect
mediat
treatment
dna
combin
imiquimod
data
quit
consist
recent
clinic
trial
use
therapeut
hpv
vaccin
conjunct
imiquimod
patient
vulvar
intraepitheli
neoplasia
studi
treatment
imiquimod
vaccin
led
clinic
respons
patient
signific
increas
local
infiltr
cell
lesion
patient
studi
observ
deplet
macrophag
tumorbear
mice
treat
imiquimod
dna
vaccin
led
loss
antitumor
effect
suggest
import
macrophag
antitumor
effect
gener
imiquimod
combin
dna
vaccin
figur
tumorbear
mice
treat
imiquimod
also
show
signific
increas
number
macrophag
tumor
microenviron
figur
taken
togeth
data
suggest
combin
dna
vaccin
imiquimod
treatment
may
result
increas
macrophag
tumor
contribut
antitumor
effect
review
see
shown
tumor
contain
signific
number
macrophag
lead
suppress
antitumor
tcell
respons
thu
facilit
tumor
growth
thu
treatment
tumor
imiquimod
dna
vaccin
may
result
switch
immunosuppress
macrophag
phenotyp
inflammatori
phenotyp
show
treatment
imiquimod
lead
increas
number
cell
cell
tumor
microenviron
figur
furthermor
antibodi
deplet
experi
indic
cell
essenti
observ
antitumor
effect
figur
nk
cell
shown
express
imiquimodmedi
activ
nk
cell
may
result
product
thu
like
nk
cell
directli
lead
cytotox
effect
nk
cell
also
lead
increas
express
may
lead
upregul
mhc
class
may
render
tumor
cell
suscept
kill
cell
observ
treatment
dna
combin
imiquimod
lead
reduct
number
myeloidderiv
suppressor
cell
mdsc
tumor
microenviron
tumorbear
mice
figur
shown
myeloidderiv
suppressor
cell
play
import
immunosuppress
role
tumor
microenviron
review
see
reduct
mdsc
may
potenti
lead
improv
antigenspecif
cell
immun
respons
result
better
tumor
kill
employ
imiquimod
tumor
treatment
signific
potenti
clinic
translat
current
one
ongo
phase
trial
assess
immunogen
safeti
toler
efficaci
detox
dna
vaccin
follow
booster
vaccin
recombin
vaccinia
express
tahpv
combin
local
appli
agonist
imiquimod
patient
high
grade
cervic
intraepitheli
neoplasia
http
applic
imiquimod
may
gener
local
inflamm
local
lesion
microenviron
thu
allow
local
immun
effector
cell
access
lesion
epithelium
patient
cin
lesion
function
tumor
destruct
local
microenviron
summari
studi
demonstr
combin
therapeut
hpv
dna
vaccin
topic
treatment
agonist
imiquimod
enhanc
antitumor
immun
induc
dna
vaccin
studi
serv
import
foundat
futur
clinic
translat
author
declar
compet
interest
cmc
involv
execut
project
involv
interpret
data
write
manuscript
cfh
tcw
provid
overal
supervis
guidanc
project
author
read
approv
manuscript
